科前生物
(688526)
| 流通市值：57.66亿 | | | 总市值：57.66亿 |
| 流通股本：4.66亿 | | | 总股本：4.66亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 373,827,539.24 | 227,536,944.76 | 949,742,023.06 | 737,863,251.81 |
| 营业收入 | 373,827,539.24 | 227,536,944.76 | 949,742,023.06 | 737,863,251.81 |
| 二、营业总成本 | 267,836,114.82 | 135,315,536.88 | 524,371,080.48 | 401,181,258.98 |
| 营业成本 | 151,692,522.85 | 81,909,523.78 | 313,671,966.29 | 243,795,691.84 |
| 税金及附加 | 5,234,423.54 | 3,344,201.3 | 6,399,678.69 | 4,947,850.1 |
| 销售费用 | 40,549,016.99 | 22,245,513.12 | 105,203,660.83 | 81,234,910.86 |
| 管理费用 | 29,648,784.13 | 13,429,405.56 | 59,837,555.5 | 43,466,248.18 |
| 研发费用 | 59,446,864.13 | 25,104,400 | 96,411,370.73 | 71,872,613.35 |
| 财务费用 | -18,735,496.82 | -10,717,506.88 | -57,153,151.56 | -44,136,055.35 |
| 其中:利息费用 | 142,141.28 | 72,173.84 | -1,773,682.84 | 269,451.82 |
| 其中:利息收入 | 18,391,939.85 | 10,229,925.76 | 56,421,355.48 | 45,438,279.37 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 18,336,038.27 | 2,366,175.01 | 33,271,389.35 | 27,620,436.69 |
| 加:投资收益 | 4,523,727.69 | 2,145,490.3 | 7,405,727.22 | -9,564,186.97 |
| 资产减值损失(新) | -8,642,244.07 | -6,310,502.25 | -12,636,565.86 | -7,925,846.66 |
| 信用减值损失(新) | -3,868,090.72 | -7,316,880.5 | 9,693,386.86 | 28,550,162.64 |
| 其他收益 | 13,049,878.98 | 7,096,490.51 | 20,009,419.46 | 14,949,832.51 |
| 四、营业利润 | 129,390,734.57 | 90,202,180.95 | 483,114,299.61 | 390,312,391.04 |
| 加:营业外收入 | 63,598.91 | 29,913.45 | 222,656 | 136,511.44 |
| 减:营业外支出 | 715,912.45 | 127,104.18 | 1,796,169.34 | 1,477,570.85 |
| 五、利润总额 | 128,738,421.03 | 90,104,990.22 | 481,540,786.27 | 388,971,331.63 |
| 减:所得税费用 | 14,014,598.37 | 11,415,862.54 | 64,599,520.14 | 52,366,559.79 |
| 六、净利润 | 114,723,822.66 | 78,689,127.68 | 416,941,266.13 | 336,604,771.84 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 114,723,822.66 | 78,689,127.68 | 416,941,266.13 | 336,604,771.84 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 115,723,217.64 | 79,236,163.81 | 418,723,155.8 | 337,791,776.24 |
| 少数股东损益 | -999,394.98 | -547,036.13 | -1,781,889.67 | -1,187,004.4 |
| 扣除非经常损益后的净利润 | 85,696,797.67 | 69,451,904.82 | 351,633,712.49 | 274,582,316.3 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.25 | 0.17 | 0.9 | 0.72 |
| (二)稀释每股收益 | 0.25 | 0.17 | 0.9 | 0.72 |
| 八、其他综合收益 | -27,779,257.48 | -7,104,812.04 | 81,279,244.34 | 47,672,522.15 |
| 归属于母公司股东的其他综合收益 | -27,779,257.48 | -7,104,812.04 | 81,279,244.34 | 47,672,522.15 |
| 九、综合收益总额 | 86,944,565.18 | 71,584,315.64 | 498,220,510.47 | 384,277,293.99 |
| 归属于母公司股东的综合收益总额 | 87,943,960.16 | 72,131,351.77 | 500,002,400.14 | 385,464,298.39 |
| 归属于少数股东的综合收益总额 | -999,394.98 | -547,036.13 | -1,781,889.67 | -1,187,004.4 |
| 公告日期 | 2026-08-27 | 2026-04-30 | 2026-04-08 | 2025-10-30 |
| 审计意见(境内) | | | 标准无保留意见 | |